{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","spread":"45.38","value":"109.45"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG005","spread":"NA","value":"246.12"},{"groupId":"OG007","spread":"26.75","value":"239.98"},{"groupId":"OG008","spread":"54.77","value":"361.30"},{"groupId":"OG009","spread":"49.71","value":"251.73"},{"groupId":"OG012","spread":"47.17","value":"325.42"},{"groupId":"OG013","spread":"56.94","value":"201.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"title":"Cmax, n=0,0,0,5,0,1, 0,15,3,8,0,0,7,16,0"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"4.29","value":"2.47"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG005","spread":"NA","value":"66.39"},{"groupId":"OG007","spread":"116.63","value":"18.17"},{"groupId":"OG008","spread":"161.52","value":"10.83"},{"groupId":"OG009","spread":"71.98","value":"18.45"},{"groupId":"OG012","spread":"108.08","value":"12.66"},{"groupId":"OG013","spread":"99.02","value":"14.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"13"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"title":"Cmin, n=0,0,0,2,0,1, 0,14,3,7,0,0,6,13,0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}